SCHEMBL5188604

SCHEMBL5188604

COc1ccc(NS(=O)(=O)c2ccccc2NC(=O)c2ccc(F)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.68
▸ SMN1; SMN2 Q16637 4/20 0.68
▸ HPGD P15428 1/20 0.68
▸ CCR8 P51685 1/20 0.63
▸ MEN1 O00255 8/20 0.62
▸ KMT2A Q03164 8/20 0.62
▸ ALDH1A1 P00352 4/20 0.62
▸ HTT P42858 2/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.62
▸ NPC1 O15118 2/20 0.59
▸ F10 P00742 1/20 0.58
▸ MAPT P10636 4/20 0.58
▸ GAA P10253 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ HDAC3 O15379 2/20 0.52
▸ HDAC2 Q92769 2/20 0.52
▸ HDAC4 P56524 1/20 0.52
▸ HDAC1 Q13547 1/20 0.52
▸ HDAC7 Q8WUI4 1/20 0.52
▸ HDAC10 Q969S8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5188667 0.86 CCR8 (0.63) LMNASMN1; SMN2HPGDCCR8MEN1
SCHEMBL5187445 0.85 SNCA (0.59) LMNASMN1; SMN2HPGDCCR8MEN1
SCHEMBL8627623 0.81 F10 (0.64) LMNASMN1; SMN2HPGDMEN1KMT2A
SCHEMBL27181622 0.81 KMT2A (0.75) LMNASMN1; SMN2HPGDMEN1KMT2A
SCHEMBL27180643 0.81 KMT2A (0.75) LMNASMN1; SMN2HPGDMEN1KMT2A
SCHEMBL1337665 0.81 CCR8 (0.89) LMNASMN1; SMN2HPGDCCR8MEN1
SCHEMBL1339700 0.81 CCR8 (0.93) LMNASMN1; SMN2HPGDCCR8MEN1
SCHEMBL11698871 0.78 CA2 (0.71) SMN1; SMN2KMT2AALDH1A1NPC1F10
SCHEMBL6403077 0.78 KMT2A (0.81) LMNASMN1; SMN2HPGDCCR8MEN1
SCHEMBL5187417 0.78 CCR8 (0.52) LMNASMN1; SMN2HPGDCCR8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421057-A4 CHEMOTHERAPEUTIC AGENTS STARPHARMA PTY LTD (AU) 2007-03-14 — — EP claimed
US-20050038248-A1 Chemotherapeutic agents STARPHARMA PTY LTD (AU) 2005-02-17 — — US claimed
EP-1421057-A1 CHEMOTHERAPEUTIC AGENTS Starpharma Limited (AU) 2004-05-26 — — EP claimed
WO-2003018536-A1 CHEMOTHERAPEUTIC AGENTS STARPHARMA LIMITED (AU) 2003-03-06 — — WO claimed
EP-1421057-A4 CHEMOTHERAPEUTIC AGENTS STARPHARMA PTY LTD (AU) 2007-03-14 — — EP disclosed
US-20050038248-A1 Chemotherapeutic agents STARPHARMA PTY LTD (AU) 2005-02-17 — — US disclosed
EP-1421057-A1 CHEMOTHERAPEUTIC AGENTS Starpharma Limited (AU) 2004-05-26 — — EP disclosed
WO-2003018536-A1 CHEMOTHERAPEUTIC AGENTS STARPHARMA LIMITED (AU) 2003-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038248-A1 Chemotherapeutic agents MKI67, PCNA, MCL1 LMNA 3779/4885SMN1; SMN2 2728/4885HPGD 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback